Early and nonreversible decrease of CD161++/MAIT cells in HIV infectionCormac Cosgrove, Paul Klenerman, Huldrych F. Günthard et al.|Blood|2012Cited by 312
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M. Gatell, Nadine Ktorza, Lambert Assoumou et al.|Clinical Infectious Diseases|2018Cited by 48
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna Gonzalez‐Cordón, Juergen Rockstroh, Lambert Assoumou et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 27
Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment TrialAlejandro Arenas‐Pinto, Birgit Grund, Shweta Sharma et al.|Clinical Infectious Diseases|2018Cited by 25
Association of HIV status with sexual function in women aged 45–60 in England: results from two national surveysNasreen Toorabally, Shema Tariq, Catherine H Mercer et al.|AIDS Care|2019Cited by 18